A retrospective analysis of the clinical data of seven acute B-lymphoblastic leukemia (B-ALL) patients with TCF3-HLF fusion gene-positive admitted to the First Affiliated Hospital of Soochow University from June 2017 to August 2022 was conducted to summarize their clinical features and prognoses. The seven B-ALL patients comprised four males and three females, with a median age of 18 (11-33) years. Five patients tested positive for CD33 expression, and four patients had a normal karyotype. Two patients had hypercalcemia at the initial diagnosis, and one patient developed hypercalcemia at relapse. Six patients presented with coagulation dysfunction at diagnosis. After induction chemotherapy, five out of seven patients achieved complete remission, of which four subsequently relapsed. Two patients did not achieve remission even after two rounds of induction chemotherapy, with one achieving complete remission after treatment with blinatumomab immunotherapy. Three patients underwent chimeric antigen receptor T cell therapy, whereas three patients subsequently underwent hematopoietic stem cell transplantation. Five patients died, while two patients survived with sustained complete remission. TCF3-HLF-positive B-ALL is rare and has a high relapse rate and poor prognosis.
回顾性分析2017年6月至2022年8月苏州大学附属第一医院收治的7例TCF3-HLF融合基因阳性的急性B淋巴细胞白血病（B-ALL）患者的临床资料，总结其临床特征及预后。7例B-ALL患者中男4例，女3例，中位年龄18（11～33）岁。5例患者CD33表达阳性，4例患者为正常染色体核型。2例患者初诊时合并高钙血症，1例患者复发时出现高钙血症，6例患者初诊时合并凝血功能障碍。7例患者接受诱导化疗后5例达完全缓解，其中4例后续复发。2例患者经2次诱导化疗后仍未缓解，其中1例接受贝林妥欧单抗免疫治疗后达完全缓解。3例患者接受嵌合抗原受体T细胞治疗，3例患者后续接受造血干细胞移植。5例患者死亡，2例患者存活且持续完全缓解。TCF3-HLF阳性B-ALL罕见，复发率高，预后差。.